Compositions for regenerating defective or absent myocardium
First Claim
Patent Images
1. An injectable graft composition for myocardial tissue regeneration, said composition comprising acellular heart extracellular matrix (ECM), said ECM comprising endogenous transforming growth factor beta (TGF-β
- ) and fibroblast growth factor-2 (FGF-2), said ECM further comprising an exogenously added glycosaminoglycan (GAG), said GAG comprising at least 0.1% by weight of said composition, said GAG being linked to said ECM, wherein said GAG stimulates angiogenic effects of FGF-2 and interacts with TGF-β
to control matrix formation and remodeling, wherein, when said composition is administered to damaged or diseased cardiovascular tissue, said composition induces stem cell proliferation and differentiation of stem cells into cardiomyocytes.
3 Assignments
0 Petitions
Accused Products
Abstract
Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.
-
Citations
10 Claims
-
1. An injectable graft composition for myocardial tissue regeneration, said composition comprising acellular heart extracellular matrix (ECM), said ECM comprising endogenous transforming growth factor beta (TGF-β
- ) and fibroblast growth factor-2 (FGF-2), said ECM further comprising an exogenously added glycosaminoglycan (GAG), said GAG comprising at least 0.1% by weight of said composition, said GAG being linked to said ECM, wherein said GAG stimulates angiogenic effects of FGF-2 and interacts with TGF-β
to control matrix formation and remodeling, wherein, when said composition is administered to damaged or diseased cardiovascular tissue, said composition induces stem cell proliferation and differentiation of stem cells into cardiomyocytes. - View Dependent Claims (2)
- ) and fibroblast growth factor-2 (FGF-2), said ECM further comprising an exogenously added glycosaminoglycan (GAG), said GAG comprising at least 0.1% by weight of said composition, said GAG being linked to said ECM, wherein said GAG stimulates angiogenic effects of FGF-2 and interacts with TGF-β
-
3. An injectable graft composition for myocardial tissue regeneration, said composition comprising acellular stomach submucosa (SS), said SS comprising endogenous transforming growth factor beta (TGF-β
- ) and fibroblast growth factor-2 (FGF-2), said ECM further comprising an exogenously added glycosaminoglycan (GAG), said GAG comprising at least 0.1% by weight of said composition, said GAG being linked to said ECM, wherein said GAG stimulates angiogenic effects of FGF-2 and interacts with TGF-β
to control matrix formation and remodeling, wherein, when said composition is administered to damaged or diseased cardiovascular tissue, said composition induces stem cell proliferation and differentiation of stem cells into cardiomyocytes. - View Dependent Claims (4)
- ) and fibroblast growth factor-2 (FGF-2), said ECM further comprising an exogenously added glycosaminoglycan (GAG), said GAG comprising at least 0.1% by weight of said composition, said GAG being linked to said ECM, wherein said GAG stimulates angiogenic effects of FGF-2 and interacts with TGF-β
-
5. An injectable graft composition for myocardial tissue regeneration, said composition comprising acellular liver basement submucosa (LBS), said LBS comprising endogenous transforming growth factor beta (TGF-β
- ) and fibroblast growth factor-2 (FGF-2), said ECM further comprising an exogenously added glycosaminoglycan (GAG), said GAG comprising at least 0.1% by weight of said composition, said GAG being linked to said ECM, wherein said GAG stimulates angiogenic effects of FGF-2 and interacts with TGF-β
to control matrix formation and remodeling, wherein, when said composition is administered to damaged or diseased cardiovascular tissue, said composition induces stein cell proliferation and differentiation of stein cells into cardiomyocytes. - View Dependent Claims (6)
- ) and fibroblast growth factor-2 (FGF-2), said ECM further comprising an exogenously added glycosaminoglycan (GAG), said GAG comprising at least 0.1% by weight of said composition, said GAG being linked to said ECM, wherein said GAG stimulates angiogenic effects of FGF-2 and interacts with TGF-β
-
7. An injectable graft composition for myocardial tissue regeneration, said composition comprising acellular liver basement membrane (LBM), said LBM comprising endogenous transforming growth factor beta (TGF-β
- ) and fibroblast growth factor-2 (FGF-2), said ECM further comprising an exogenously added glycosaminoglycan (GAG), said GAG comprising at least 0.1% by weight of said composition, said GAG being linked to said ECM, wherein said GAG stimulates angiogenic effects of FGF-2 and interacts with TGF-β
to control matrix formation and remodeling, wherein, when said composition is administered to damaged or diseased cardiovascular tissue, said composition induces stem cell proliferation and differentiation of stem cells into cardiomyocytes. - View Dependent Claims (8)
- ) and fibroblast growth factor-2 (FGF-2), said ECM further comprising an exogenously added glycosaminoglycan (GAG), said GAG comprising at least 0.1% by weight of said composition, said GAG being linked to said ECM, wherein said GAG stimulates angiogenic effects of FGF-2 and interacts with TGF-β
-
9. An injectable graft composition for myocardial tissue regeneration, said composition comprising acellular placental extracellular matrix (ECM), said ECM comprising endogenous transforming growth factor beta (TGF-β
- ) and fibroblast growth factor-2 (FGF-2), said ECM further comprising an exogenously added glycosaminoglycan (GAG), said GAG comprising at least 0.1% by weight of said composition, said GAG being linked to said ECM, wherein said GAG stimulates angiogenic effects of FGF-2 and interacts with TGF-β
to control matrix formation and remodeling, wherein, when said composition is administered to damaged or diseased cardiovascular tissue, said composition induces stem cell proliferation and differentiation of stem cells into cardiomyocytes. - View Dependent Claims (10)
- ) and fibroblast growth factor-2 (FGF-2), said ECM further comprising an exogenously added glycosaminoglycan (GAG), said GAG comprising at least 0.1% by weight of said composition, said GAG being linked to said ECM, wherein said GAG stimulates angiogenic effects of FGF-2 and interacts with TGF-β
Specification